<DOC>
	<DOCNO>NCT00010322</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Toremifene may fight breast cancer block uptake estrogen tumor cell . Atamestane may fight breast cancer block production estrogen . It yet know toremifene effective without atamestane . PURPOSE : Randomized phase III trial compare effectiveness toremifene without atamestane treat postmenopausal woman metastatic breast cancer .</brief_summary>
	<brief_title>Toremifene With Without Atamestane Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare time progression postmenopausal woman metastatic breast cancer treat toremifene without atamestane . II . Compare response rate , overall survival , duration response , time treatment failure patient treat regimen . III . Compare safety profile regimens patient population . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord study center . Patients randomize one two treatment arm . Arm I : Patients receive oral toremifene daily oral atamestane twice daily . Arm II : Patients receive oral toremifene arm I oral placebo twice daily . Treatment continue 12-30 month absence disease progression unacceptable toxicity . Patients follow every 12 week survival . PROJECTED ACCRUAL : A total 594 patient ( 297 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Atamestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Bidimensionally measurable disease Lesion least 2 cm least 1 diameter No failure prior adjuvant antiestrogens within first 12 month treatment No progression disease therapy prior aromatase inhibitor selective estrogen receptor modulators ( SERMs ) ( include SERMs prevention osteoporosis ) No history know central nervous system ( CNS ) metastases No bone metastases tumor manifestation Hormone receptor status : Estrogen receptor and/or progesterone receptor positive PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Postmenopausal Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 9 g/dL Platelet count least 100,000/mm3 WBC least 2,000/mm3 Hepatic : AST ALT great 2.5 time upper limit normal ( ULN ) Bilirubin great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Other : No significant neurological dysfunction include seizure clinical sign significant neurological diseases No active malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No contraindication toremifene excipients excipients atamestane Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No prior hormonal therapy metastatic disease At least 12 month since prior adjuvant antiestrogens No concurrent SERMs estrogenic androgenic hormone No concurrent aromatase inhibitor Radiotherapy : No concurrent radiotherapy except palliation bone metastases Surgery : Not specify Other : No prior enrollment study At least 30 day since prior investigational drug No concurrent investigational drug Concurrent bisphosphonates bone metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>